MILWAUKEE, Aug. 10, 2020 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Vaxart (Nasdaq: VXRT) resulting from inaccurate statements Vaxart made regarding its internal controls, business practices, financial statements and prospects.
Click here to learn more about the investigation: http://ademilaw.com/case/vaxart-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on whether Vaxart issued false and misleading statements regarding its business practices and prospects. Specifically, Vaxart announced that it had been selected for the federal program Operation Warp Speed to develop drugs for coronavirus. It has since been revealed that Vaxart, in fact, was not selected to receive significant financial support from Operation Warp Speed.
If you wish to obtain additional information or have information about this investigation of Vaxart, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, http://ademilaw.com/case/vaxart-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Ademi & O'Reilly, LLP
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi & O'Reilly, LLP